Metformin has been used to treat type 2 diabetes for decades. Today, it is also one of the most discussed medicines in longevity research.
Why?
Metformin affects several biological pathways that are also involved in aging. Research in animals and observational studies in humans have therefore raised an important possibility: could this established diabetes medicine also influence how we age?
But the key question is much more demanding:
Does metformin actually slow aging in humans?
Why Is Metformin Being Studied for Longevity?
Aging involves many interconnected biological changes. These include altered nutrient sensing, mitochondrial dysfunction, chronic low-grade inflammation and changes in cellular metabolism.
Metformin can influence several of these processes.
This makes it scientifically interesting as a potential gerotherapeutic — an intervention intended to influence biological mechanisms associated with aging.
There is another reason for the interest. Metformin is already widely used in medicine, and decades of clinical experience have provided extensive information about its effects and safety in appropriate patients.
That makes metformin very different from a completely new experimental anti-aging compound.
What Have Animal Studies Shown?
Some particularly interesting recent evidence comes from non-human primates.
In a 40-month study in cynomolgus monkeys, researchers used multiple molecular and biological measurements to investigate the effects of long-term metformin treatment.
One reported finding was a 6.41-year deceleration in plasma proteomic biological age. The study also found broader molecular and tissue changes consistent with effects on biological aging.
This is scientifically important because non-human primates are biologically closer to humans than many commonly used laboratory animals.
But the distinction is critical: this was not a human study.
Changes in biological-age measurements in monkeys do not prove that metformin slows aging or extends healthy lifespan in people.
What Do We Know in Humans?
Metformin has established clinical benefits for people with appropriate medical indications, particularly type 2 diabetes.
Observational studies have also reported associations between metformin use and outcomes such as mortality and some age-related diseases. These findings have contributed to the interest in metformin as a potential longevity intervention.
However, observational studies cannot prove that metformin itself slows aging. People taking metformin can differ from comparison groups in many ways, and these differences may influence the results.
Most importantly, we still lack definitive randomized clinical evidence demonstrating that metformin, when used specifically as a longevity intervention, slows human aging or extends healthy lifespan in otherwise healthy people.
Why Is TAME Important?
The Targeting Aging with Metformin (TAME) initiative represents an important approach to testing the geroscience hypothesis in humans.
Instead of asking whether metformin prevents only one specific disease, the concept is to examine whether it can delay the development of several major age-related diseases as a combined outcome.
This reflects a central idea of geroscience: if biological aging contributes to many chronic diseases, influencing aging-related mechanisms might potentially delay several diseases rather than treating each one separately.
TAME is therefore important not because it has already proved that metformin slows aging, but because it represents a way of testing this hypothesis clinically.
Should Healthy People Take Metformin for Longevity?
Current evidence does not establish metformin as a longevity treatment for healthy people.
Metformin is a prescription medicine, not a general anti-aging supplement. Like any medication, it can cause adverse effects and should be used when there is an appropriate medical indication and individual clinical assessment.
Promising biological mechanisms, observational associations and animal experiments are important parts of scientific discovery.
But they are not the same as evidence that a medicine extends healthy human life.
For longevity medicine, the decisive question is whether metformin can meaningfully preserve health, delay multiple age-related diseases or extend healthy lifespan in humans.
That has not yet been proven.
